← Leaderboards
Dennis M Black
Mayo Clinic Rochester
$9,656,727
Attributed
$21,762,827
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,080,402 · 7
FDA$682,425 · 3
By mechanism
R01$16,238,326 · 2
N01$1,945,597 · 1
U01$1,902,633 · 4
P30$1,095,165 · 2
R21$581,106 · 1
Top collaborators
- Annette L Adams7 shared
- Clifford J Rosen7 shared
- Douglas C Bauer6 shared
- Sundeep Khosla5 shared
- Elizabeth J. Shane4 shared
- Marcella Donovan Walker1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Sundeep Khosla$91,221,003
- Elizabeth J. Shane$22,663,624
- Heidi Maria Connolly$53,000
- Megan M Weivoda$4,293,867
- Samantha R Weaver$682,833
Others in their field
Top investigators on “Osteoporosis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Steven R Cummings · University Of California San Francisco$56,375,786
- Richard A Gibbs · Baylor College Of Medicine$49,965,365
- Peter J. Snyder · University Of Pennsylvania$36,531,878
- Douglas P. Kiel · Hebrew Rehabilitation Center For Aged$32,610,184
- Eric S. Orwoll · Oregon Health And Science University$28,146,073
Research focus
OsteoporosisWomanEpidemiologyFractureDesignOsteoporosis With Pathological FractureBone DensityPreventionSafetyClinical TrialsRisk FactorsFundingFracture RiskHigh RiskFemoral FracturesCostPopulation StudyCohortBiometryCohort StudiesPhysiciansProgramsPharmaceutical PreparationsRadiological Imaging
Grant awards (31)
Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial$2,330,081
R01 · FY2025 · AG
Pooling International Cohort Studies of Long-Term Bisphosphonate Use and Atypical Femur Fractures$835,420
R01 · FY2025 · AR
Pooling International Cohort Studies of Long-Term Bisphosphonate Use and Atypical Femur Fractures$111,795
R01 · FY2025 · AR
Pooling International Cohort Studies of Long-Term Bisphosphonate Use and Atypical Femur Fractures$50,320
R01 · FY2025 · AR
Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial$2,489,289
R01 · FY2024 · AG
Pooling International Cohort Studies of Long-Term Bisphosphonate Use and Atypical Femur Fractures$985,389
R01 · FY2024 · AR
DDT-BMQ-000054: Planning for biomarker qualification, implementation and dissemination for BMD as a surrogate biomarker in future osteoporosis treatment trials: the SABRE project$250,000
U01 · FY2024 · FD · contact PI
Coordination of Consortium Activities for RFA-AG-22-018$74,598
R01 · FY2024 · AR · contact PI
Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial$2,456,365
R01 · FY2023 · AG
Pooling International Cohort Studies of Long-Term Bisphosphonate Use and Atypical Femur Fractures$1,021,258
R01 · FY2023 · AR
Epidemiology, Biostatistics and Study Design (EBSD) Core$145,350
P30 · FY2023 · AR · contact PI
Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial$2,405,613
R01 · FY2022 · AG
Pooling International Cohort Studies of Long-Term Bisphosphonate Use and Atypical Femur Fractures$1,130,390
R01 · FY2022 · AR
DDTBMQ000054: Regulatory qualification for DXA bone mineral density as a surrogate endpoint for fracture risk in osteoporosis trials$225,766
U01 · FY2022 · FD · contact PI
Epidemiology, Biostatistics and Study Design (EBSD) Core$145,350
P30 · FY2022 · AR · contact PI
Beta1-selective blockade for prevention of postmenopausal bone loss: A randomized controlled trial$2,347,808
R01 · FY2021 · AG
Epidemiology, Biostatistics and Study Design (EBSD) Core$145,350
P30 · FY2021 · AR · contact PI
Epidemiology, Biostatistics and Study Design (EBSD) Core$145,350
P30 · FY2020 · AR · contact PI
Regulatory qualification for DXA bone mineral density as a surrogate endpoint for fracture risk in osteoporosis trials$206,659
U01 · FY2019 · FD · contact PI
Epidemiology, Biostatistics and Study Design (EBSD) Core$144,450
P30 · FY2019 · AR · contact PI
Cellular Mechanisms of PTH1R Activation with Osteoporosis Treatments$278,349
R21 · FY2018 · AR
Cellular Mechanisms of PTH1R Activation with Osteoporosis Treatments$302,757
R21 · FY2017 · AR
Epidemiology and Biostatisctics$214,871
P30 · FY2015 · AR · contact PI
Epidemiology and Biostatisctics$154,444
P30 · FY2014 · AR · contact PI
Trial Of Late SURFactant (TOLSURF) to Prevent BPD-Data Coordinating Center$395,927
U01 · FY2013 · HL · contact PI
Trial Of Late SURFactant (TOLSURF) to Prevent BPD-Data Coordinating Center$269,535
U01 · FY2012 · HL · contact PI
Trial Of Late SURFactant (TOLSURF) to Prevent BPD-Data Coordinating Center$180,534
U01 · FY2011 · HL · contact PI
Trial Of Late SURFactant (TOLSURF) to Prevent BPD-Data Coordinating Center$174,709
U01 · FY2010 · HL · contact PI
Trial Of Late SURFactant (TOLSURF) to Prevent BPD-Data Coordinating Center$199,503
U01 · FY2009 · HL · contact PI
PTH &ALDENRONATE COMBINATION TREATMENT OSTEOPOROSIS$1,001,657
N01 · FY2000 · AR
PTH &ALDENRONATE COMBINATION TREATMENT OSTEOPOROSIS$943,940
N01 · FY2000 · AR